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Abstract
Background: Preterm delivery (PTD) is a significant public health problem associated with greater
risk of mortality and morbidity in infants and mothers. Pathophysiologic processes that may lead to
PTD start early in pregnancy. We investigated early pregnancy peripheral blood global gene
expression and PTD risk.
Methods: As part of a prospective study, ribonucleic acid was extracted from blood samples
(collected at 16 weeks gestational age) from 14 women who had PTD (cases) and 16 women who
delivered at term (controls). Gene expressions were measured using the GeneChip® Human
Genome U133 Plus 2.0 Array. Student's T-test and fold change analysis were used to identify
differentially expressed genes. We used hierarchical clustering and principle components analysis
to characterize signature gene expression patterns among cases and controls. Pathway and
promoter sequence analyses were used to investigate functions and functional relationships as well
as regulatory regions of differentially expressed genes.
Results: A total of 209 genes, including potential candidate genes (e.g. PTGDS, prostaglandin D2
synthase 21 kDa), were differentially expressed. A set of these genes achieved accurate pre-
diagnostic separation of cases and controls. These genes participate in functions related to immune
system and inflammation, organ development, metabolism (lipid, carbohydrate and amino acid) and
cell signaling. Binding sites of putative transcription factors such as EGR1 (early growth response
1), TFAP2A (transcription factor AP2A), Sp1 (specificity protein 1) and Sp3 (specificity protein 3)
were over represented in promoter regions of differentially expressed genes. Real-time PCR
confirmed microarray expression measurements of selected genes.
Conclusions: PTD is associated with maternal early pregnancy peripheral blood gene expression
changes. Maternal early pregnancy peripheral blood gene expression patterns may be useful for
better understanding of PTD pathophysiology and PTD risk prediction.
Published: 10 December 2009
BMC Pregnancy and Childbirth 2009, 9:56 doi:10.1186/1471-2393-9-56
Received: 22 June 2009
Accepted: 10 December 2009
This article is available from: http://www.biomedcentral.com/1471-2393/9/56
© 2009 Enquobahrie et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Pregnancy and Childbirth 2009, 9:56 http://www.biomedcentral.com/1471-2393/9/56
Page 2 of 16
(page number not for citation purposes)
Background
Preterm delivery (PTD) is a significant global public
health problem affecting ~12-15% of all deliveries [1]. It
is associated with greater risk of mortality and morbidity
in infants and mothers and significant financial burden
[2].
PTD is a complex cluster of problems associated with
socio-economic, socio-demographic, socio-behavioral,
environmental, medical, biological and genetic risk fac-
tors [3-8]. A number of pathophysiological pathways
including chronic systemic inflammation and infection,
endothelial dysfunction, oxidative stress, placental
ischemia and reperfusion and neuro-endocrine altera-
tions have been identified to be associated with PTD
[6,9,10].
Variations in a number of candidate genes (e.g. TNF-
alpha, IL-1RA, IL4R, MMP9, MMP1, TLR4) have been
identified in both human and experimental studies [1,2].
Due to the diverse pathopysiologic processes associated
with PTD, single candidate gene profiles may not ade-
quately portray the multitude of pathogenetic changes
associated with PTD. In addition, substantial evidence has
been described for contributions of gene-environment
interactions to the incidence of PTD [11,12]. Since gene
expressions are influenced by both genetic variations and
environmental exposures, global gene expression profil-
ing studies may help to generate testable hypothesis
related to the role of genes across the genome and poten-
tial gene-environment interactions in PTD.
Previous studies primarily evaluated gene expression on
tissue, principally placenta collected after delivery [13-
18]. Since evaluation of early pregnancy tissue changes on
placenta in relation to PTD is associated with risk, most
studies on placenta before delivery were experimental.
Thus, inference on temporal relationships was limited.
Peripheral blood gene expression profiling, which can be
done at any point in pregnancy, is associated with mini-
mal risk and has shown promising results in investiga-
tions of other disease processes (such as cancer,
cardiovascular diseases, and environmental health) [19-
23]; and, could be applied to investigations of PTD.
Substantial evidence, including work from our group,
supports the thesis that pathophysiologic changes, includ-
ing system pathologies, leading up to PTD start early in
pregnancy [24-26]. Evaluating early pregnancy peripheral
blood genome-wide expression will help add to the prog-
nostic value of traditional parameters, identify potential
biological targets for prevention and treatment, improve
discrimination of sub-groups in a complex pathology
such as PTD and develop diagnostic tests.
In this pilot case control study, nested within an ongoing
prospective study, we investigated early pregnancy periph-
eral blood genome-wide gene-expression profiles of 14
women who had PTD and 16 women who had term deliv-
ery. We evaluated transcriptional gene expression patterns
associated with PTD in an effort to develop predictive
tools for PTD. Functions and functional relationships of
differentially expressed genes were investigated to better
understand pathophysiologic processes underlying PTD.
Finally, promoter sequences analysis was conducted to
investigate whether common transcription factors could
account for co-expression of genes associated with PTD.
Methods
Overview
In a pilot nested case control study among participants of
an ongoing prospective cohort study, we investigated
early pregnancy differential peripheral blood gene expres-
sion among women who delivered preterm and controls
who delivered at term.
Study population
The study was conducted using information collected
from participants of an ongoing prospective cohort study,
the Omega study, conducted at the Center for Perinatal
Studies (CPS) at Swedish Medical Center in Seattle, Wash-
ington. The Omega study was designed to examine meta-
bolic and dietary predicators and other risk factors of
pregnancy complications including preeclampsia, gesta-
tional diabetes mellitus and preterm labor. Selection of
study participants has been described before [27,28].
Briefly, participants were recruited from women attending
prenatal care clinics affiliated with Swedish Medical
Center. Women who initiate prenatal care prior to 20
weeks gestation were eligible to participate. Ineligibility
criteria included younger than 18 years of age, not speak-
ing or reading English, not planning to carry the preg-
nancy to term, and/or not planning to deliver at the
Swedish Medical Center. More than 80% of approached
women consented to participate and more than 95% were
followed through pregnancy completion. PTD was
defined as delivery before completion of 37 weeks of ges-
tation after pregnancy lasting at least 20 weeks of gesta-
tion (PREBIC Genetics Working Group) [3]. Estimated
date of conception (EDC) assessed using maternal report
of last menstrual period (LMP) combined with ultra-
sound at ≤20 weeks gestation was used to determine PTD.
Women with multi-fetal gestation and women delivering
infants with malformations were excluded. Controls were
selected among women who completed 37 weeks of ges-
tation frequency matched for maternal age and gesta-
tional age at blood collection. We initially identified 16
cases and 16 controls for the study. The procedures used
in the Omega Study are in agreement with the protocolsBMC Pregnancy and Childbirth 2009, 9:56 http://www.biomedcentral.com/1471-2393/9/56
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approved by the Institutional Review Board of Swedish
Medical Center. All participants provide written informed
consent.
Data Collection
Information on risk factors was collected using in-person
interviews, blood collection and medical records abstrac-
tion. Following enrollment, in-person interviews were
conducted to collect data on socio-demographic charac-
teristics, occupation, reproductive and medical histories,
alcohol and tobacco consumption, environmental
tobacco smoke exposure, medications, height, weight,
physical activity, and familial histories of medical condi-
tions. At or near the time of in-person interviews (16
weeks of gestation on average), trained phlebotomists col-
lected 2.5 mLs (in duplicates) of antepartum peripheral
blood from each participant in PAXgene™ Blood RNA
tubes, part of a PAXgene™ Blood RNA System (PAXgene
Blood RNA Kit) (PreAnalytiX, Qiagen, Inc) [29]. The PAX-
gene™ Blood RNA System enables consolidation of key
steps of peripheral blood collection, nucleic acid stabiliza-
tion and RNA purification to reduce RNA degradation,
inhibit or eliminate gene induction and make possible
long-term storage of peripheral blood samples. Further,
the system allows for multiple Blood RNA tube freeze-
thaw cycles without affecting RNA yields. Samples were
immediately aliquoted and stored at -80°C until RNA
extraction and analysis. After delivery, trained personnel
abstracted data from Omega participants' maternal and
infant medical records to ascertain pregnancy outcomes.
Total RNA extraction
The PAXgene Blood RNA Kit (PreAnalytiX, Qiagen, Inc)
was used for extraction and purification of total RNA from
peripheral blood, according to manufacturers' protocols.
The procedure, briefly, was as follows. Initial equilibra-
tion of samples to room temperature for two hours was
followed by centrifugation of cell lysates. The pellets were
washed and resuspended in optimized buffers and incu-
bated with proteinase K to bring about protein digestion.
Centrifugations through the PAXgene Shredder spin col-
umns were carried out to homogenize the cell lysate and
remove residual cell debris. The supernatant of the flow-
through fraction was then transferred to a fresh microcen-
trifuge tube. Ethanol was added to adjust binding condi-
tions and the lysate was applied to a PAXgene RNA spin
column. During centrifugation, RNA was selectively
bound to the PAXgene silica membrane as contaminants
pass through. Remaining contaminants were removed in
several efficient wash steps. Between wash steps, the silica-
membrane is treated with DNase I to remove any residual
DNA contaminants. After wash steps, pure RNA samples
were eluted in a buffer, heat denatured at 65°C and
immediately chilled on ice. Extracted RNA was stored at -
80°.
RNA quantity measurement and quality control
Total RNA concentration was determined by ultraviolet
absorbance at 260 nm (A260) by direct measurement (i.e
non-diluted) on a NanoDrop ND1000 spectrophotome-
ter (ThermoFisher Scientific, Wilmington, DE). Purity of
RNA was assessed by evaluating readings at 260 nm and
280 nm (A260/A260) that provides an estimate of purity of
RNA with respect to contaminants that absorb UV, such as
protein. All samples had A260/280 values greater than 2.0
indicating a high level of purity. Agilent 2100 Bioana-
lyzer-based quality control criteria were also used to meas-
ure RNA quality (Agilent Technologies Inc, Palo Alto, CA).
The RNA Integrity Number (RIN), based on a 10 point
scale, is an objective measure of total RNA quality and
integrity based on several features of the RNA profile
(including the fraction of the sample in the region of 18S
and 28S RNA and the relative height of the 28S peak).
One sample which had met the spectrophotometric QC
criteria (A260/A280 = 2.04), had poor results on the bio-
analyzer (RIN = 2.3) indicating a high level of RNA degra-
dation and was therefore deemed to be of insufficient
quality for gene expression measurement. Samples were
then kept in frozen storage at -80°C. All RNA samples,
including reference RNAs, underwent quality control
checks and were labeled using the same standardized pro-
tocols.
RNA amplification, fragmentation and labeling
All sample target preparations were conducted in accord-
ance with the guidelines detailed in the technical manuals
for the NuGEN™ Ovation™ Whole Blood Reagent and
NuGEN™ Ovation™ RNA Amplification System V2
(amplification) in combination with the NuGEN™ FL-
Ovation™ cDNA Biotin Module V2 (fragmentation and
labeling). Briefly, these steps are described below.
Total RNA (50 ng) was amplified using the NuGEN™ Ova-
tion™ Whole Blood Reagent and NuGEN™ Ovation™ RNA
Amplification System V2. First-strand synthesis of cDNA
was carried out using a unique first-strand DNA/RNA chi-
meric primer mix, resulting in cDNA/mRNA hybrid mol-
ecules. Following fragmentation of the mRNA component
of the cDNA/mRNA molecules, second-strand synthesis
was carried out and double-stranded cDNA was formed
with a unique DNA/RNA heteroduplex at one end. In the
final amplification step, RNA within the heteroduplex was
degraded using RNaseH, and replication of the resultant
single-stranded cDNA was achieved through DNA/RNA
chimeric primer binding and DNA polymerase enzymatic
activity. The amplified single-stranded cDNA was purified
using the Zymo Research Clean and Concentrator™-25 Kit
to allow for accurate quantitation of the cDNA and to
ensure optimal performance during the fragmentation
and labeling processes. The single stranded cDNA was
assessed for quality using spectrophotometric methods inBMC Pregnancy and Childbirth 2009, 9:56 http://www.biomedcentral.com/1471-2393/9/56
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combination with the Agilent Bioanalyzer. For the labe-
ling step, 4.4 μg of amplified single-stranded cDNA was
fragmented and labeled using the FL-Ovation™ cDNA
Biotin Module V2. The enzymatically and chemically frag-
mented product (50-100 nt) was labeled via the attach-
ment of biotinylated nucleotides onto the 3'-end of the
fragmented cDNA.
Hybridization, Washing and Staining
The resultant fragmented and labeled cDNA was added to
the hybridization cocktail in accordance with the NuGEN
and Affymetrix guidelines for hybridization onto Affyme-
trix Human Genome U133 Plus 2.0 GeneChip® Arrays
(Affymetrix, Sunnyvale, CA). This array platform offered a
comprehensive coverage (comprised of more than 54,000
probe sets and 1,300,000 distinct oligonucelotide features
representing over 47,000 transcripts and variants, includ-
ing 38,500 well-characterized human genes) of the tran-
scribed human genome on a single array. Following
hybridization for 18 hours at 45°C, the arrays were
washed and stained on the GeneChip® Fluidics Station
450 (Affymetrix, Sunnyvale, CA) using the appropriate
fluidics script, before being inserted into the Affymetrix
autoloader carousel and scanned using the GeneChip®
Scanner 3000 (Affymetrix, Sunnyvale, CA). All scanned
array images were visually inspected for chip surface arti-
facts that could adversely impact the data, and then data
from each array was quantified using GeneChip® Operat-
ing Software (Affymetrix, Sunnyvale, CA). GCOS auto-
matically acquires and analyzes image data, defines probe
cells and computes an intensity value for each probe cell.
These intensity values were pre-processed for analysis
using quality control filters and normalization.
GeneChip quality controls and normalization
A number of quality control checks were conducted to
evaluate GeneChip quality. First, background values
(which can range from 20 to 100) of GeneArray scanners
calibrated to the new PMT setting (10% of maximum)
were assessed for comparability. Second, the GAPDH gene
was used to assess RNA sample and assay quality specifi-
cally for the GeneChip array. The signal values for the 3'
probe set for GAPDH were compared to the 5' probe set.
The ratio of the 3' to the 5'probe sets were expected to be
no more than 3. Third, hybridization controls on the
GeneChip array (four E. Coli genes, bioB, bioC and bioD
and the cre gene) were spiked into each sample independ-
ent of RNA sample preparation to evaluate hybridization
efficiency. Fourth, raw noise (Q value), a measure of pixel-
to-pixel variation of probe cells on a GeneChip array due
to operation-associated electrical noise of the GeneArray
scanner (unique to each scanner) was evaluated. Arrays
that were scanned on the same scanner should ideally
have comparable Raw Q values. Fifth, PolyA control
genes, comprised of the dap, lys, phe, thr and trp genes
from B. subtilis, were amplified and spiked into the RNA
samples prior to amplification to serve as internal control
genes. Finally, data were normalized using an error-
weighted model with Rosetta Resolver Error Models
(Rosetta, Seattle, WA) [30]. In order to distinguish 'signal'
and 'noise' intensity, background filtering was done by
removing error model based "absent-called" sequences
and those with intensity values lower than 2× standard
deviations of chip background.
Real time quantitative polymerase chain reaction (RT-
qPCR) experiment
A real time quantitative polymerase chain reaction (RT-
qPCR) experiment was conducted to measure expression
of nine selected genes that were differentially expressed in
peripheral blood collected from women who delivered
preterm as a confirmatory step of microarray based gene
expression measures. In the first step, 1 μg total RNA from
each of the 30 samples was reverse transcribed using the
Transcriptor first strand cDNA synthesis kit (Roche
Applied Science, Indianapolis, IN) according to manufac-
turer's instructions. Briefly, 1 μl of anchored-oligo (dT) 18
primer (2.5 μM final concentration) was added to each
sample and heated at 65°C for 10 min and immediately
cooled to 4°C. A mastermix was prepared on ice for all the
samples with final concentrations of 1× Transcriptor
reverse transcriptase reaction buffer (containing 8 mM
MgCl2), 20 U of Protector RNase inhibitor, 1 mM each
dNTP and 10 U of Transcriptor reverse transcriptase. The
samples were mixed by pipetting and incubated in a ther-
mocycler at 55°C for 30 min followed by 85°C for 5 min
to inactivate the reverse transcriptase. Additional 4 sam-
ples were selected from the 30 in which the Transcriptor
reverse transcriptase was replaced by PCR grade water and
used to perform reverse transcription negative control
reactions. The concentration of each reverse transcription
was determined spectrophotometrically and diluted to 40
ng/μl using PCR-grade water for use as template for qPCR.
The qPCR reactions were performed using the Roche
LightCycler 480®  Probes kit and the LightCycler 480®
instrument according to the Lightcycler 480® probes mas-
ter protocol. Pre-designed exon spanning Taqman® assays
for each gene target were obtained from Applied Biosys-
tems (Foster City, CA).
Each individual assay was run on an individual 96-well
plate in duplicate for each sample; and, 2 reverse tran-
scription negative controls and 2 no template control
wells were included with each assay. A mastermix was pre-
pared for each assay on ice to enable a final reaction con-
centration of 1× primer-probe mix and 1 Lightcycler 480®
Probes Master. Twelve μl of mastermix was dispensed into
the appropriate wells of a Lightcycler 480® 96 well plate
and 8 μl of template cDNA at 40 ng/μl was added. The
plate was sealed and centrifuged for 2 min at 1,500 × g.
The Lightcycler PCR was set-up for single FAM labeled
probes and underwent an initial pre-incubation at 95°CBMC Pregnancy and Childbirth 2009, 9:56 http://www.biomedcentral.com/1471-2393/9/56
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for 10 min followed by 45 cycles of 95°C for 10 sec and
annealing and extension at 60°C for 30 sec with fluores-
cence captured following each extension step. Assay sensi-
tivity, reproducibility and transcript concordance with
microarray platforms and primer efficiency were assessed
and assay optimization was carried out to achieve better
sensitivity, specificity, reproducibility and a wider linear
dynamic range.
Individual reactions were characterized by the PCR cycle
at which fluorescence first rises above threshold back-
ground fluorescence (the threshold cycle, Ct). The assay
relies on fluorescence signal, which is proportional to the
amount of DNA produced during each PCR cycle. This
correlation between fluorescence and amount of ampli-
fied DNA permits accurate quantification of target over a
wide dynamic range, while retaining high sensitivity and
specificity making this experiment useful as a confirma-
tory tool for microarray gene expression measurements.
Samples were processed simultaneously to avoid batch-
to-batch variation. Normalization of expression measure-
ments were done using three reference genes (RHOA,
KHDRBS1 and BAT1) which were selected based on their
non-variant gene expression in the microarray platform
across cases and controls.
Data analysis
After data normalization, principle components analysis
(PCA) was used to identify significant outliers based on
expression measurements. Based on this analysis, one
sample (PTD case), was identified as a significant outlier
was removed from further analysis. Thus, for the final ana-
lytic set included 14 PTD cases and 16 controls.
Fold change of comparison for each sequence across the
two groups (cases and controls) based on normalized data
together with Student's t-test (two sample, unequal vari-
ances) were performed in order to identify differentially
expressed genes. Volcano plot was used to depict distribu-
tions of fold change (log2 [fold change]) for biological
significance and Student's t-test p-values (-log10 [p-
value]) for statistical significance. Genes that met cutoffs
of absolute fold change differences ≥ 1.5 and Student's t-
test (p-values < 0.05) constituted the set of differentially
expressed genes associated with PTD. Two-Dimensional
hierarchical clustering analysis (2-D), using Cluster and
TreeView softwares that employ a hierarchical clustering
approach based on Pearson's correlation coefficient and
PCA techniques were used to evaluate whether differen-
tially expressed genes cluster arrays into groups (PTD and
term delivery groups) [31,32].
Relationships between differentially expressed genes were
investigated in pathway analysis using Ingenuity Pathway
Analysis (IPA) software (Ingenuity, Redwood City, CA). In
IPA, Ingenuity Pathways Knowledge Base (IPKB), a pub-
lished and peer-reviewed database and computational
algorithms will be used to identify local networks that are
particularly enriched for the Network Eligible Genes,
defined as genes in our list of differentially expressed
genes with at least one previously defined connection to
another gene in the IPKB. A score, that takes into account
the number of Network Eligible Genes and the size of the
networks, was calculated using a Fisher's exact test as the
negative log of the probability that the genes within that
network are associated by chance. Gene-enrichment of
networks (network score), measured in IPA, using a mod-
ified Fisher's exact test was used to rank biological signifi-
cance of gene function networks in relation to PTD.
In exploratory analysis, we applied Partek's single-level
cross-validation method (Partek® software, Partek Inc., St.
Louis, MO) using a portion of the samples in each group
as training dataset to generate a candidate signature gene
list, and tested them on the rest of the arrays as the testing
dataset to evaluate if the gene list would correctly identify
array's group.
Common regulatory sequences for the differentially
expressed genes as well as their cognate regulators (tran-
scription factors (TFs)) were searched using ConTra (con-
served transcription factor binding sites, TFBs) and
MAPPER. ConTra is a promoter alignment analysis tool
for identification of transcription factor binding sites
across species. MAPPER (multi-genome analysis of posi-
tions and patterns of elements of regulation) is a platform
for the computational identification of transcription fac-
tor binding sites (TFBSs) in multiple genomes which uses
an innovative technique that combines TRANSFAC and
JASPAR data with the search power of profile hidden
Markov models. Since genes with similar expression pro-
files are likely to encode interacting proteins, we also eval-
uated protein-protein interactions (PPI) using
Cytoprophet, a Cystoscape plug-in for protein and
domain interaction network inference and results of our
gene expression study (protein counterparts of differen-
tially expressed genes) [33].
In the confirmatory RT-qPCR study, we repeated fold
change analysis to evaluate differential expression meas-
ured using RT-qPCR for the selected genes from our set of
differentially expressed genes in the microarray experi-
ment. In this analysis, gene expression normalization (ini-
tially using RHOA gene) was done by determining delta
Ct, where ΔCt = average Ct_target - average Ct_normalizer.
Then the difference of mean Ct values between test and
control was determined, ΔΔCt = ΔCt_control - ΔCt_test.
Determination of fold Change (FC) was based on FC =BMC Pregnancy and Childbirth 2009, 9:56 http://www.biomedcentral.com/1471-2393/9/56
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Primer EfficiencyΔΔCt. True fold change was represented by
the following: if FC > 1, true fold change = FC; if FC< 1,
true fold change = -1/FC.
Results
In this study, we investigated 14 PTD cases and 16 con-
trols (Table 1). Blood was collected at 16 weeks of gesta-
tion, on average, comparably between cases and controls.
A third of PTD cases followed spontaneous onset of labor
while a third each followed preterm rupture of membrane
and medically indicated labor induction and/or Cesarean
delivery. Most study participants were white. Higher rates
of preeclampsia, and chronic hypertension as well as
smoking during the current pregnancy were observed for
PTD cases compared with controls. PTD cases had also
higher pre-pregnancy body mass index (BMI) compared
with term controls.
A volcano plot that demonstrates the Student's t-test
based p-value and fold change differences in gene expres-
sion between the 14 PTD cases and 16 controls is shown
in Figure 1. There are a total of ~47,400 probe sets (tran-
scripts) representing >38,500 genes on the GeneChip. Of
these, 1579 probe sets representing 209 genes were up or
down regulated (99 up regulated and 110 down regu-
lated) in PTD cases using the criteria of p-value < 0.05 and
absolute fold change > 1.5 (Additional File 1). The result-
ing gene list included strong candidate genes such as
LOC442421, a gene similar to prostaglandin E receptor 4,
prolactin, Protein C, cystathionine-beta-synthase, tumor
necrosis factor receptor superfamily, member 13B, and
FLT1 as well as a number of novel genes with potential sig-
nificance such as TEX1 (testis expressed gene 1), Transge-
lin and methylthioadenosine phosphorylase.
PCA using these 209 genes and the 30 arrays was able to
clearly separate the two groups of PTD cases and term
delivery controls (Figure 2). Similarly, in the 2-D cluster-
ing analysis, as shown in the heat map in Figure 3, the 209
differentially expressed genes grouped most of cases and





GA at delivery, weeks* 32.3 (2.1) 39.1 (0.8)
GA at blood collection, weeks* 16.5 (2.1) 15.8 (1.4)
Preterm delivery types
Spontaneous labor 4 (28.6) 0 (0.0)
Preterm PROM 5 (35.7) 0 (0.0)
Other medically indicated 5 (35.7) 0 (0.0)
Maternal Age, years* 33.0 (4.2) 33.1 (3.8)
20-34 years 8 (57.1) 9 (56.3)
35 and above years 6 (42.9) 7 (43.7)
Race
White 8 (57.1) 15 (93.7)
African American 2 (14.3) 0 (0.0)
Other 4 (28.6) 1 (6.3)
Pre-gestational BMI, kg/m2* 29.6 (11.9) 23.8 (6.2)
Multiparous 6 (42.9) 9 (56.3)
Multigravida 10 (71.4) 12 (75.0)
Cesarean delivery 4 (28.6) 2 (12.5)
Smoked in pregnancy 2 (14.3) 1 (6.3)
Preeclampsia 4 (28.6) 0 (0.0)
Gestational diabetes 2 (14.3) 2 (12.5)
Diabetes mellitus 0 (0.0) 0 (0.0)
Chronic hypertension 4 (28.6) 1 (6.3)
Chorioamnionitis 1 (7.1) 2 (12.5)
Abruptio placenta 1 (7.1) 0 (0.0)
IUGR 0 (0.0) 0 (0.0)
Cervical insufficiency 1 (7.1) 0 (0.0)
*Mean, otherwise n (%)
Abbreviations: GA: gestational age, PROM: premature rupture of membrane, IUGR: intrauterine growth retardation, BMI: body mass index; kg/m2: 
kilogram/meter2BMC Pregnancy and Childbirth 2009, 9:56 http://www.biomedcentral.com/1471-2393/9/56
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controls separately. In the exploratory analysis using
Partek's automated model selection method, overall, 1-
level cross validation rates based on over 10 testing sets
were between 65-69%. In other words, a gene list gener-
ated from each training dataset gave a correct prediction
rate of around 65-69% (about two out of three).
Results from functions and functional relationships of the
differentially expressed genes using IPA are shown in
Table 2 and Additional Files 2, 3, 4, 5, 6 and 7. Genes in
our list of differentially expressed genes over represented
six networks. The top network (Score = 49) as well as
another network among significantly represented net-
works (Score = 19) has functions in the immune system
and inflammation, lymphatic system, tissue morphology
and hematological system development and function.
Other networks that were also well represented included
those related to development (cellular and organ develop-
ment involving the nervous system, reproductive system
and cardiovascular system) and metabolism (lipid, carbo-
hydrate and amino acid). In addition, networks in the IPA
analysis provide supportive evidence for genes such as
NFKB, P38MAPK, Mapk, Akt, Vegf, retinoic acid, HOXA9,
TNF, dihydrotestosterone, thyroid hormone, CDKNA1,
sulfotransferase, Ggt, Oleic acid, progesterone, CCL2 and
KNG which were not differentially expressed in our data
set but could play significant roles in PTD.
In the promoter analysis, a number of common regulatory
sequences, motifs, were identified. These sequences corre-
sponded to binding sites of transcription factors TFAP2A
(transcription factor AP2A), EGR1 (early growth response
factor 1), Sp1 (specificity protein 1) and Sp3 (specificity
protein 3) on genes that were differentially expressed in
PTD cases compared to controls (Figure 4). In the pre-
dicted protein domain interaction analysis based on our
gene expression results, evidence for significant interac-
tions of the EGR1 protein domain with other putative
protein domains is presented (Figure 5). Further, several
protein domains of potential importance in PTD were
identified such as TR145 and TUT1.
In the confirmatory RT-qPCR experiment, expressions of
nine genes (ABCB9, ABP1, CBS, FCER1A, PRKAA1,
PTGDS, SLC16A7, TNFRSF13B and QRSL1) differentially
expressed in PTD cases in the microarray experiment were
evaluated. Three housekeeping genes (RHOA, KHDRBS1
and BAT1) were used in the experiment. For six of the nine
genes, similar fold change differences and were observed
between microarray and RT-qPCR expression measure-
ments for an overall concordance rate of about 67% (Fig-
ure 6).
Discussion
In this study, we show that early pregnancy peripheral
blood gene expression is associated with PTD. Differen-
tially expressed genes participate in diverse cellular path-
ways including immune function, inflammation, organ
development, hematological system, metabolism and cell
signaling underscoring the different pathophysiologic
processes leading to PTD. Further, binding sites for tran-
scription factors, EGR1, TFAP2A, Sp1 and Sp3 were over-
represented in promoter sequences of differentially
expressed genes, potentially accounting for observed co-
expressions.
Several pathophysiological mechanisms contribute to the
occurrence of PTD following spontaneous preterm labor,
PPROM or other medically indicated PTD. These include
inflammation and infection, hormonal deregulation,
decidual hemorrhage, uterine over-distension as well as
local cervical abnormalities [34-39]. Previous uterine and
cervical gene expression studies, mostly experimental,
have shown that labor is associated with up/down regula-
tion of genes involved in chemokine/cytokine activation,
signal transduction, acute phase response, growth-differ-
entiation, adhesion, extracellular matrix remodeling, con-
traction (calcium signaling, ion channels), complement
and coagulation cascades, kinases, VEGF-family signaling,
arginine and proline metabolism and apoptosis [35-39].
In the current study, supportive evidence for differential
expression of genes participating in similar pathways in
peripheral blood (e.g. FLT1) in early pregnancy is pre-
sented.
Proinflammatory cytokines and immune related chemok-
ines stimulate prostaglandin production and uterine con-
traction through mechanisms that involve cycloxygenase-
Volcano plot of gene expression differences between cases  and controls Figure 1
Volcano plot of gene expression differences between 
cases and controls. Volcano plot distributions of fold 
change (log2 [fold change]) (X-axis) and Student's t-test p-
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2 [34,40,41]. They act on cervical smooth muscles
enhancing cervical ripening, activate matrix metallopro-
teinasess expression; and, increase protease production
leading to extracellular matrix degradation, related cervi-
cal changes and premature rupture of membrane
[34,40,41]. Both term and preterm labor are associated
with a reduction in the percentage of monocytes express-
ing MHC class II depicting a pattern referred to as "mono-
cyte hyporesponsiveness" or "immune paresis" [42]. HLA-
DOB that suppresses peptide loading of MHC class II mol-
ecules by inhibiting HLA-DM, was upregulated in our
study. Several other genes participating in immune func-
tion and inflammation (such as LILRB5, TIRAP, CD69
and CD53) were up regulated in our study.
Hormonal dysregulation (related to progesterone, pros-
taglandins and prolactin) has been associated with PTD.
Progesterone withdrawal or a progestin-resistant environ-
ment may precede preterm labor [40]. Prostaglandin sub-
types (E and F), released by the membranes in response to
stretch and actions of pro-inflammatory cytokines, act not
only upon the myometrium and cervix, but may also exert
paracrine/autocrine effects on cell viability and matrix
protein integrity [41]. On the other hand, other prostag-
landins (such as subtype D) have roles in pregnancy
maintenance [43]. LOC442421, a gene coding for a pro-
tein similar to the prostaglandin E4 receptor was up regu-
lated in the current study. Further, PTGDS, a gene coding
prostaglandin D2 synthase was down regulated in our
study. The progesterone responsiveness of prostaglandin
receptors is in part regulated by transcription factors
belonging to the class of homeobox genes [40]. HOXA1,
a previously described breast cancer related gene [44] that
belongs to this class, was down regulated in our study. The
PRL gene coding for prolactin, a growth hormone associ-
ated with lactation and that has been suggested for use in
PTD prediction from cervicovaginal washings [45], was
down regulated in our study.
PTD is frequently associated with abruption and/or decid-
ual hemorrhage. These events result in intense local
thrombin generation, binding to protease activated recep-
tor-1 to stimulate decidual protease production promot-
ing rupture of membranes and myometrial contractions
to induce PTD [41]. Genes participating in the coagula-
tion cascade including PROC and VWCE were differen-
tially expressed in peripheral blood in our study.
Principal component analyses Figure 2
Principal component analyses. Principal component analysis results of all samples (14 cases and 16 controls) using 209 dif-
ferentially expressed genes. (Red/right: cases, Blue/left: controls).BMC Pregnancy and Childbirth 2009, 9:56 http://www.biomedcentral.com/1471-2393/9/56
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Cervical remodeling (including softening, ripening, dila-
tion and labor) associated with PTD is related to collagen
solubility [46-49]. Since, cervix is composed of extracellu-
lar matrix components such as collagen, elastin, prote-
oglycans and others, systemic effects can influence cervical
remodeling [46,47]. Fortunato et al demonstrated an
increased mRNA expression for MMP2, MMP9, and MT1-
MMP and a decreased expression for TIMP2 in prema-
turely ruptured membranes [48]. Suggestions for further
studies to determine steps in collagen synthesis, cross-
linking and fibril assembly that may be altered in early
pregnancy have been put forth [47]. Our study has identi-
fied a number of potential genes such as COL23A1,
P4HA2, participating in collagen metabolism and up reg-
ulated in peripheral blood in early pregnancy. Myometrial
activation leading to PTD may result from the coordinated
expression of a cassette of contraction-associated proteins
that include ion channels (calcium and potassium), ago-
nist receptors (i.e. oxytocin and prostaglandin) and gap
junctions [50,51]. A number of genes involved in ion
channel function regulation (S100A5, SLC24A6,
KCNMB4, KCNH2 and ABP1) were differentially
expressed in our study.
Labor involves a number of interacting pathomechanisms
that are integrated by various regulatory mechanisms
involving upstream regulators and/or transcription factors
[52]. These regulators include a) basic domains (e.g. AP-1,
cAMP, CRE) b) zinc coordinating DNA binding domains
(e.g. SP1 and nuclear factors such as PPAR) c) homeo-
domain transcription factors and d) beta-scaffold tran-
scription factors (e.g. NFAT, NFKB and STAT) [52]. For
instance, NFKB regulates functional progesterone with-
drawal, pro-labor mediators such as cytokines, phosphol-
ipid metabolites and release of ECM remodeling enzymes
[52]. In our study, direct (e.g. GATA2) and indirect (in
pathway analysis, e.g. NFKB) evidence for involvement of
these regulatory transcription factors in PTD is presented.
For instance strong evidence for role of EGR1, from both
promoter analysis and protein-protein-domain interac-
Heat map illustration of samples and selected differentially expressed genes Figure 3
Heat map illustration of samples and selected differentially expressed genes. Selected genes (N = 209) differentially 
expressed (upregulated: shades of red and downregulated: shades of green) in whole blood associated with preterm delivery 
(rows) and participants (columns, cases = pink and controls = green) grouped according to level and nature of gene expression 
(genes) and similarity of expression profiles (participants) and subjected to hierarchical tree clustering.BMC Pregnancy and Childbirth 2009, 9:56 http://www.biomedcentral.com/1471-2393/9/56
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Table 2: Gene networks* overrepresented by differentially expressed genes associated with preterm delivery
Genes in Network Score Focus genes Functions
14-3-3, AKAP12, Akt, ALK, Ap1, BIRC5, CaMKII, 
CD53, CD69, CDC25A, CYP2E1, E2f, FAM46A, 
FCER1A, FLT1, GATA2, HDC, Histone h3, 
HMGA2, IGHM, Mapk, NEFL, NFkB, P38 MAPK, 
PDGF BB, PRL, PROC, RGS7, SYNPO2, 
TAGLN, TIRAP, TNFRSF13B, TOP2A, Vegf, 
ZBTB10
49 24 Immune and Lymphatic System Development and Function, 
Tissue Morphology, Hematological System Development and 
Function
BMI1, CBS, CDCA5, CDKN2A, DHX8, DHX15, 
EEF1A1, EXOSC4, GAS7, GFM1, GPRC5A, 
HADHA, HOXA1, HOXA2, HOXA9, HOXA3 
(includes EG:3200), HOXB2, HOXB9, HOXC5, ID4, 
KIF1B, MBNL1, MEG3 (includes EG:55384), 
MEIS2, MPHOSPH1, P4HA2, PBX1, PBXIP1, 
RCBTB2, RECQL4, retinoic acid, SKIV2L, TLX2, 
TMSB10, WSB1
24 14 Cellular Development, Nervous System Development and 
Function, Cell Cycle
AK2, androsterone, CCNI, CDK2, CKB, 
dihydrotestosterone, ECH1, GPD2, HIPK1, 
HSD17B6, KAP, LOC645619, MAK, ME1, MMP17, 
MS4A3, NCKAP1, NR6A1, RASAL2, SAMD4A, 
SEC22B, SLC16A7, SLC1A4, SLC45A3, 
SMURF1, SRGAP2, SVIL, TALDO1, thyroid 
hormone, TNF, WDR90, WT1, WTAP, YWHAG, 
ZNF7
22 13 Organ Development, Organ Morphology, Reproductive System 
Development and Function
ABP1, AKT1, amino acids, ANK3, CDKN3, 
CDKN1A, CHST13, EGF, HGF, HS3ST2, HS3ST5, 
HS3ST6, HS3ST3A1, HS3ST3B1, HS3ST4 (includes 
EG:9951), MYBL2, NEK4, NUSAP1, PCDHGA11, 
PCDHGC3, PELO, PRKAA1, RAMP1, SMP2A, 
SPG20, sulfotransferase, SULT1A2, SULT1A4, 
SULT1B1, SULT1C2, SULT1C4, SULT4A1, TERT, 
UST, ZNF622
22 13 Carbohydrate Metabolism, Amino Acid Metabolism, Post-
Translational Modification
ABCB9, ACSBG1, ACSL3, ACSL4, ACSL5, ACSL6, 
ATP, butyric acid, C1QTNF2, CPA3, DDAH1, Ggt, 
GGT2, GGT3, GGT6, GGTL3, GGTL4, GGTLA1, 
GGTLA4, HOM-TES-103, IL13, JARID1A, KRAS, 
MTAP, NFYB, NR3C1, oleic acid, PITRM1, RERE, 
RPL41, SLC26A6, SLC7A5, ST8SIA4, TRIM45, 
ZNF610
19 12 Lipid Metabolism, Small Molecule Biochemistry, Molecular 
Transport
ACE2, AGT, BDKRB1, CCL2, CD177, CEBPB, CIITA, 
CRYBB2, CSF3, DARC, EMR1, ENPEP, EP300, 
HDAC1 (includes EG:3065), HLA-DOA, HLA-DOB, 
HLA-DQB1, HOPX, HP, IK, INMT, KNG1 (includes 
EG:3827), LPP, MCOLN2, MSH5, NAP1L1, PFKFB3, 
progesterone, PTGDS, RFXAP, RRM2, SALL1, 
SERBP1, TMEM176A, XPNPEP1
19 12 Cell-To-Cell Signaling and Interaction, Inflammatory Disease, 
Cardiovascular System Development and Function
*The networks were generated through the use of Ingenuity Pathways Analysis (Ingenuity® Systems, http://www.ingenuity.com). Each gene identifier 
was mapped to its corresponding gene object in the Ingenuity Pathways Knowledge Base (IPKB). These genes were overlaid onto a global molecular 
network developed from information contained in the IPKB. Network enrichment is then assessed using a network score (negative log of p-values 
of Fisher tests). Focus genes (in bold) are genes identified in our list of differentially expressed genes. Networks shown here are those with 
network scores > 3.0.BMC Pregnancy and Childbirth 2009, 9:56 http://www.biomedcentral.com/1471-2393/9/56
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tion analysis, supporting previous reports [38], is pre-
sented. EGR1 can be a potential target for enhancing
preventive, early prediction or therapeutic efforts in PTD.
Previous gene expression studies investigating preterm
labor and delivery were conducted on cervical and uterine
tissue, mostly post partum under experimental settings.
While evidence for changes in gene expression preceding
clinical signs of labor have been put forward [51], to our
knowledge, we are not aware of any "published study"
that investigated gene expression in peripheral blood in
early pregnancy to predict PTD. The timing of activation
of each cascade of activities related to PTD [37] is not
clear. Our study provides hypothesis-generating evidence
for PTD risk factors and their interactions, particularly for
those involving systemic processes. While PTD remains a
significant public health problem, methodological limita-
tions have hindered research in this area. Development of
methods utilizing use of peripheral blood for investigat-
ing risk factors of PTD has great potential in understand-
ing pathophysiologic pathways and predictive
applications [53]. Other strengths of our study include the
following. First, the study was conducted nested within a
larger well-characterized prospective pregnancy cohort.
Second, we used appropriate measures to collect and sta-
bilize maternal antepartum peripheral blood samples for
isolating high quality pure mRNA. Third, we conducted
extensive evaluation of differentially expressed genes
using pathway, promoter and protein-protein-domain
interaction analysis using powerful statistical and bioin-
formatics tools to gain insights into processes underlying
the pathophysiology of PTD.
Promoter analysis results of differentially expressed genes Figure 4
Promoter analysis results of differentially expressed genes. Inferred network of differentially expressed genes (Red = 
up regulated and Green = down regulated) in preterm delivery and transcription factors (White). Transcription factors were 
identified by their binding to over expressed promoter sequences in the differentially expressed genes.BMC Pregnancy and Childbirth 2009, 9:56 http://www.biomedcentral.com/1471-2393/9/56
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Several potential limitations of our pilot study deserve
mention. First, single measurement of peripheral blood
gene expression may not provide a full picture of the gene
expression changes associated with PTD. Second, since
PTD is associated with a set of diverse pathological condi-
tions, some of the observed changes may be related to the
disease conditions and not to PTD specifically. Third, we
may not have enough power to assess all expression
changes associated with PTD. In absence of previous
pilots for gene expression variations in PTD, we were not
able to assess the statistical power of our study. Fourth,
while we have frequency matched cases and controls for
maternal age, and gestational age at blood draw, residual
confounding by these variables or uncontrolled con-
founding by others (e.g. race) may account for these gene
expression differences. Fifth, inter-individual variability of
gene expression in peripheral blood related to differences
in cellular constituency of collected samples may account
for differences. Finally, since we are evaluating early preg-
nancy changes, most of our findings in gene expression
changes are likely to identify systemic disease processes
that start early in pregnancy and are associated with PTD.
Nevertheless, given the substantial burden of PTD and the
concordance of our findings with other cross sectional
studies, our preliminary findings, if confirmed, are likely
to have strong clinical and public health relevance.
In the confirmatory RT-qPCR experiment, 3 of the 9 genes
(ABCB9, PRKAA1 and TNFRSF1) we evaluated did not
have concordant expression measures with the microarray
Protein domain interactions of differentially expressed genes Figure 5
Protein domain interactions of differentially expressed genes. Predicted domain interactions of differentially 
expressed genes: For instance, EGR1 can potentially interact (not only with its targets gene motifs) with the domain of many of 
the genes forming the inferred network genes. The thickness of the edge shows extent of interaction.BMC Pregnancy and Childbirth 2009, 9:56 http://www.biomedcentral.com/1471-2393/9/56
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experiment. We investigated potential reasons (primer
efficiencies, splice variants, choice of calibrator genes for
normalization) for this discordance. Including primer
efficiencies in recalculation of fold change differences did
not improve the discordance. Of the three genes, one,
PRKAA, had an Affymetrix target region located in a non-
overlapping region with the ABI assay primer set. How-
ever, no information could be found in the public
sequence or published domain for evidence of PRKAA
splice variants. Further in-depth sequence analysis is
needed to investigate this lack of overlap which may
account for the discordance. Choice of alternative house-
keeping genes (KHDRBS1 and BAT1) did not improve the
concordance. The concordance observed in our study
(67%) is comparable to the concordance from other pub-
lished microarray studies, given the small number of
genes assessed (nine). For example, two previous studies
reported confirmation of 70% to 75% of gene expression
trends determined by cDNA microarray analysis using
real-time RT-PCR [54,55].
In summary, we have shown that PTD is associated with
maternal early pregnancy blood gene expression changes.
Maternal early pregnancy peripheral blood gene expres-
sion patterns may be useful for better understanding of
the pathophysiology of PTD and risk prediction. Further-
more, since evaluating gene expression of peripheral
blood in early pregnancy is practical, knowledge and
experience gained from this area of research may allow for
similar applications in other pregnancy disorders.
Conclusion
Early pregnancy peripheral blood gene expression is asso-
ciated with PTD. Differentially expressed genes participate
in diverse cellular pathways including immune function,
inflammation, organ development, hematological sys-
tem, metabolism and cell signaling underscoring the dif-
ferent pathophysiologic processes leading to PTD.
Further, binding sites for transcription factors, EGR1,
TFAP2A, Sp1 and Sp3 were overrepresented in promoter
sequences of differentially expressed genes, potentially
accounting for observed co-expressions. Maternal early
pregnancy blood gene expression patterns may be useful
for better understanding of PTD pathophysiology and
PTD risk prediction.
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